Research – QuoteMedia Inc. – Initiation Report

Friday, July 12, 2019

QuoteMedia, Inc. (QMCI)

A David Versus Goliath Story

QuoteMedia, based in Fountain Hills, Arizona, provides cloud-based financial data, market news feeds, and financial software solutions. Its customers include financial service companies, online brokerages, clearing firms, banks, media portals, public corporations and individual investors. The company provides a single source solution providing products such as streaming quotes, charting, historical data, technical analysis, news and research. Information can customized and provided to multiple platforms including terminals and mobile devices.

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Initiating coverage. We are initiating with an Outperform rating based on the company’s favorable revenue and cash flow growth prospects and compelling stock valuation. The company is closely held and could be subject to Penny Stock rules. As such, the shares are considered to be suitable for speculative investors.
  • Why QuoteMedia? The company plays in a large market, has a scalable business model, favorable pricing ability, and is flexible to compete for…..



    Get full report on Channelchek desktop.




*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

News – Are Driverless Vehicles Being Over-Hyped?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

Along with electric vehicles, the concept of autonomous vehicles is garnering significant media attention as technology leaders, including Apple (AAPL), Google (GOOG), Amazon (AMZN), and Uber (UBER) seek to establish market leading positions in the nascent technology. While concepts include driverless taxis and/or delivery trucks, the technology has already advanced from driver assistance to an ability to pilot automated vehicles in a controlled environment. While still too early for practical application and mass adoption, technology advancements in this area could have profound implications for not just urban planning, jobs and convenience, but for social and political policies as well. Are there parallels to be drawn from President Trump’s statement following the tragic Boeing 737 Max incident when he tweeted “I see it all the time in many products. Always seeking to go one unnecessary step further, when often old and simpler is better”? Below we scratch the surface on each side of the argument.

Research – DLH Holdings (DLHC) – An Early Look at the Combined DLH and Social & Scientific Systems

Wednesday, July 10, 2019

DLH Holdings Corp. (DLHC)

An Early Look at the Combined DLH and Social & Scientific Systems

DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offer services to several government agencies which include the Department of veteran affairs, Department of health and human services, Department of defense and other government agencies.    

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Management Call. DLH management recently held a conference call to provide additional detail of the June 10th announcement of the Social & Scientific Systems (SSS) acquisition. The $70 million purchase, $63 million net of tax benefits, valued SSS at roughly 1x sales and 11x EBITDA. These multiples are in-line with industry metrics.
  • Acquisition Begins VA COMP De-Risking.. SSS significantly de-risks the potential loss of the VA-COMP business, in our view. SSS provides diversification for DLH, both on a revenue and end customer basis, and will broaden and… 


Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Trovagene (TROV) – What does Colorectal Cancer Trial Add?

Wednesday, July 10, 2019

Trovagene Inc. (TROV)

What does Colorectal Cancer Trial Add?

TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.    

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Colorectal cancer is the third active clinical trial assessing Onvansertib.. Trovagene initiated patient enrollment in a Phase 1b/2 clinical trial for the treatment of KRAS-mutated metastatic colorectal cancer (mCRC) on July 9, 2019. In addition to this trial, Trovagene is currently evaluating Onvansertib in a Phase 1b/2 study of acute myeloid leukemia (AML), and in a Phase 2 trial of metastatic castration-resistant prostate cancer (mCRPC).
  • Unfulfilled need in colorectal cancer treatment.. Among the three cancer types targeted by Onvansertib, colorectal cancer represents the largest… 


Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

News – Mission (Im)possible: (Un)druggable RAS?

Drugging
the Undruggable: The War Against RAS Oncoproteins

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)  
The RAS pathway is one of the most frequently dysregulated pathways in cancer. Approximately 30% of tumors harbor activating RAS gene mutations. There are three main isoforms of oncogenic RAS: KRAS, HRAS and NRAS.  Among these genes, KRAS is the most frequently mutated (~90% of pancreatic cancers, ?35% of colon cancers). In comparison, NRAS and HRAS are mutated in a lesser number of cancer patients (15% of melanomas and 4% of head and neck cancer patients).
The RAS protein family consists of low molecular weight guanosine 5?-triphosphate (GTP), a building block of protein synthesis. GTP-binding proteins orchestrate a variety of cellular signaling networks, which are essential to regulate a variety of cellular functions including cell proliferation, differentiation, and cell survival. The three RAS proteins (N-RAS, H-RAS and K-RAS) oscillate between an active (GTP-bound) and an inactive (GDP-bound) state. When RAS genes are mutated (typically at codon 12, 13 or 61), RAS proteins are constitutively activated (i.e. continuously binding to GTP), which induces a pro-tumorigenic state characterized by unregulated cell proliferation and resistance to apoptosis (i.e. evading death signals). Constitutively activated RAS proteins trigger downstream signaling responsible for phenotypic traits known as hallmark of cancer including:

  • aberrant cell proliferation
  • resistance to apoptosis
  • increase in migration, cell invasion and metastasis to different tissues
  • escaping the anti-tumoral immune response

The phenotype of many cancer cells is determined by RAS-dependent aberrant signal transduction pathways involving various oncogenic proteins acting downstream of RAS (Exhibit 1).
The high mutational rate of RAS genes in cancer patients, combined with the fundamental role of RAS proteins in cancer biology, makes the RAS family of oncoproteins a primary therapeutic target. Since its discovery in 1982, both academia and industry have made significant efforts to develop an anti-cancer medicine targeting RAS. Despite these intensive efforts, there are no FDA approved anti-RAS drugs at present. For this reason, RAS is perceived as “undruggable”.
In 2013, the National Cancer Institute launched the “RAS
initiative
” to expand efforts toward the discovery and development of novel medicines for the treatment of RAS-caused cancers. Since then, the initiative has focused on answering the key questions:

  1. Can it be targeted directly or indirectly?
  2. Which effector pathway of RAS is most crucial for cancer initiation and progression?
  3. Are specific mutants or isoforms required to be specifically targeted for effective inhibition?

The enthusiasm generated by the “RAS initiative” has sparked renewed interest by the biotech and pharma industries, which has restarted their own RAS programs.
Exhibit
1.
RAS signaling pathways involved in human cancer


Source:
Seminars in Cancer Biology 54 (2019) 138–148

Research – Vectrus (VEC) – What does Advantor Systems add to Vectrus?

Tuesday, July 9, 2019

Vectrus (VEC)

What does Advantor Systems add to Vectrus?

Vectrus Inc is a U.S.-based company that provides services to the U.S. government. The company generates nearly all its revenue from the United States Department of Defense. The company offerings are categorized into three types; infrastructure asset management services, logistics and supply-chain management services, and information technology and network communication services.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Advantor Systems Acquisition. Yesterday, Vectrus announced the acquisition of Advantor Systems Corporation, a leading provider of integrated electronic security systems to the federal government. Vectrus acquired the $35 million revenue company for $44 million, using cash on hand and the Company’s credit facility.
  • Market Leader. Deployed at over 2,000 client sites worldwide, Advantor is the only vertically integrated and accredited C3 networked security technology platform. Advantor clients include…


    Get full report on Channelchek desktop.




*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – One Stop Systems (OSS) – What Impact Will the $60 Million OEM Agreement Have?

Tuesday, July 9, 2019

One Stop Systems (OSS)

What Impact Will the $60 Million OEM Agreement Have?

One Stop Systems Inc is US-based company which is principally engaged in designing, manufacturing, marketing high-end systems for high performance computing (HPC) applications. The company offers custom servers, compute accelerators, solid-state storage arrays and system expansion systems.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • OEM Agreement. OSS signed an exclusive five-year OEM and supply agreement with major customer Disguise Systems for media and entertainment servers. The agreement solidifies the relationship between the firms, in our view.
  • $60 Million Minimum Level. The agreement calls for a minimum $60 million of purchases over the five-year term, with the minimums rising from $10 million to…


    Get full report on Channelchek desktop.




*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Dyadic (DYAI) – VTT to Continue Validation of C1 Platform in Bioproduction.

Monday, July 8, 2019

Dyadic International (DYAI)

VTT to Continue Validation of C1 Platform in Bioproduction.

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the industrially proven hyper productive engineered fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.

 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating. 

  • Extension of Research Agreement with VTT. Dyadic has extended its research and development contract with VTT Technical Research Centre through June 2022. VTT is a Finland-based, state owned non-profit company, which provides research and innovation services. Dyadic and VTT continuing long history of collaboration to improve production of target proteins and establish glyco-engineering for C1 platform.  
  • Terms of the Agreement. The terms of the agreement include a total payment of €2.52(EUR) million throughout the 36 months of contract period. The agreement also grants… 





Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Fed Rate Cut: Who Does it Affect?

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section) 

With the ongoing trade tensions with China, the Fed is unsure of how this will affect the U.S economy in the long term, but talks of interest rate cuts are on the table, although the U.S. is expected to have a strong 2019. The S&P just hit a record high for the first time in nearly two decades, but many still believe the interest rate cut is needed. Many policy makers want to wait for a stronger sign of an economic downturn, while others believe that the cut should be implemented over the next six months.

Exploring a New Frontier: 5G Networking

(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)

5G describes the next-generation in technology used in wireless networking and cellular devices capabilities replacing the existing LTE mobile networks. 5G wireless networking enables a new horizon in the creation of consumer experience incorporating revolutionary new speeds in data transmission, latency reduction, and supported reliability for cloud and computing technology. It has begun to branch out throughout the United States and already plays a key role in foreign technology markets. 5G allows for a new era of consumer and manufacturer benefits, supplementing the job market through development and providing users with expanded connectivity and interactivity.

IPO Podcast Series: Kathy Ireland

IPO Podcast Series: Kathy Ireland.

Parlayed teen modeling into supermodel then super mogul… Her multi-billion-dollar empire is now ranked among the top 50 licensing companies in the world with annual sales of $2 billion. Her personal fortune is over $500 million.. Full episode available July 18.

The most innovative Ideas, the inspirational People behind them, and the wealth of Opportunities they create… that’s IPO from Channelchek, hosted by Brant Pinvidic

watch the IPO series trailer

Research – Entravision Communications (EVC) – Sheds Light on the Matter

Wednesday, July 3, 2019

Entravision Communications (EVC)

Sheds Light on the Matter

Entravision Communications Corporation is a diversified Spanish-language media company utilizing a combination of television and radio operations to reach Hispanic consumers across the United States, as well as the border markets of Mexico.

Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Underperforming the broader market. Mining companies (as measured by the XME) declined 4.4% during the June quarter versus a 3.8% increase in the S&P 500 Index. Notably, after posting 2.9% and 15.4% declines in April and May, the XME rose 16.3% in June on the back of higher gold prices which rose 8.0%. During the first half of 2019, the XME was up 8.4% but still lagged the S&P 500 Index which appreciated 17.4%.
  • Key drivers of precious metals performance. In our view, monetary policy, geopolitical risk and trade will most likely…



    Get full report on Channelchek desktop.




*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Industry Report – Minerals – Are Mining Stocks Poised for a Better Second Half?

Wednesday, July 3, 2019

Minerals Industry Report

Are Mining Stocks Poised for a Better Second Half?

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to end of report for Analyst Certification & Disclosures

  • Underperforming the broader market. Mining companies (as measured by the XME) declined 4.4% during the June quarter versus a 3.8% increase in the S&P 500 Index. Notably, after posting 2.9% and 15.4% declines in April and May, the XME rose 16.3% in June on the back of higher gold prices which rose 8.0%. During the first half of 2019, the XME was up 8.4% but still lagged the S&P 500 Index which appreciated 17.4%.
  • Key drivers of precious metals performance. In our view, monetary policy, geopolitical risk and trade will most likely drive movements in gold for the remainder of the year. While fears of a global or U.S. recession appear to have been deferred for the moment, they have not faded, in our view.
  • Base metals remain linked to economic growth expectations. With respect to base metals, issues around trade and economic growth will continue to influence demand expectations.
  • Mining stocks offer an attractive option for gaining metals exposure. In our view, mining stocks are an attractive way to gain exposure to metals given their leverage to strengthening metals prices. Precious metals equities may provide a hedge against volatility in the equity markets and offer diversification benefits.

Metals and Mining Commentary – Second Quarter 2019

Mining companies (as measured by the XME) declined 4.4% during the June quarter versus a 3.8% increase in the S&P 500 Index.  Notably, after posting 2.9% and 15.4% declines in April and May, the XME rose 16.3% in June on the back of higher gold prices which rose 8.0%.  During the first half of 2019, the XME was up 8.4% but still lagged the S&P 500 Index which appreciated 17.4%.  During the second quarter, the price of gold increased 9.1%, while silver increased 1.3%.  Futures suggest gold above $1,400 an ounce in 2020, with silver prices in the mid- $15 range.  The gold/silver ratio was 92.0x at the close of the quarter and we still maintain our view that silver is undervalued relative to gold and thus could represent greater long-term price appreciation potential.

Among base metals, copper and lead fell 7.8% and 5.3% during the second quarter, while zinc eked out a 1.3% gain.  During the first half of 2019, gold was up 9.9%, silver declined 0.9%, copper rose 3.0%, lead fell 4.7% and zinc was down 0.9%.  What can investors expect for the remainder of 2019?

A few of the key contributors to gold’s strength in June included a rather dovish posture from the Federal Reserve Open Markets Committee when it decided to maintain the target range for federal funds rate and suggested the potential for the future rate cuts by mentioning in its release that it could “act as appropriate to sustain the expansion.”  Accommodation by the the Fed could send the dollar lower which would be supportive of precious metals.  Second, trade concerns, particularly with China, helped sustain gold’s rally along with increasing geopolitical tensions, most notably with Iran.  Interestingly though, second quarter sales of gold bullion by the U.S. Mint totaled a modest 19,000 ounces, compared to 90,000 ounces during the first quarter and 77,000 ounces during the prior year period, which implies that the June rally was likely driven by the purchase of gold-backed exchange-traded products rather than physical coin investment.  We generally view physical buying as an indicator of the breadth of such rallies.  For example, the U.S. Mint has been challenged in past years to keep up with demand when prices were rising.

In our view, monetary policy, geopolitical risk and trade will most likely drive movements in gold for the remainder of the year.  While fears of a global or U.S. recession appear to have been deferred for the moment, they have not faded, in our view.  Underscoring concerns about economic growth, a more dovish posture by the U.S. Federal Reserve and other Central Banks, including the European Central Bank and Bank of Japan, may strengthen gold’s appeal, especially when one considers that real interest rates are negative in some countries.  We note that, according to the World Gold Council, first quarter global gold demand increased 7% on a yearover-year basis with Central Bank purchases representing the largest since the first quarter of 2013,  China and Russia have been buyers as they have sought to diversify away from the U.S. dollar.

With respect to base metals, issues around trade and economic growth will continue to influence demand expectations.  While these will influence near and intermediate prices for copper, we are very constructive on the long-term outlook due to growing sources of demand that include components for electric vehicles, charging stations and electronics and support investment in new sources of supply.

In our view, mining stocks are an attractive way to gain exposure to metals given their leverage to strengthening metals prices.  Additionally, we think precious metals equities also may provide diversification benefits and may provide a hedge against volatility in the equity markets. 

GENERAL DISCLAIMERS: All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc. (“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.

This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results.

Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.

IMPORTANT DISCLOSURES: This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.

The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.

Company Specific Disclosures: The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.

Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months

ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE

Senior Equity Analyst focusing on Basic Materials & Mining. 20 years of experience in equity research. BA in Business Administration from Westminster College. MBA with a Finance concentration from the University of Missouri. MA in International Affairs from Washington University in St. Louis. Named WSJ ‘Best on the Street’ Analyst and Forbes/StarMine’s “Best Brokerage Analyst.” FINRA licenses 7, 24, 63, 87.

WARNING

This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc..

RESEARCH ANALYST CERTIFICATION

Independence Of View

All views expressed in this report accurately reflect my personal views about the subject securities or issuers.

Receipt of Compensation

No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.

Ownership and Material Conflicts of Interest

Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.

NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same.

Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.

Noble Capital Markets, Inc.

225 NE Mizner Blvd. Suite 150

Boca Raton, FL 33432

561-994-1191

Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer. Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer. Member – SIPC (Securities Investor Protection Corporation)

Report ID: 10979